Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization. - Friedman, Katie Paul; Gagne, Matthew; Loo, Lit-Hsin; Karamertzanis, Panagiotis; Netzeva, Tatiana; Sobanski, Tomasz; Franzosa, Jill A; Richard, Ann M; Lougee, Ryan R; Gissi, Andrea; Lee, Jia-Ying Joey; Angrish, Michelle; et al. (Toxicological Sciences, 2020)